News stories about Humana (NYSE:HUM) have trended somewhat positive on Saturday, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Humana earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news coverage about the insurance provider an impact score of 45.0932251164217 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Are Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or Humana Inc. (NYSE:HUM) Ready to Rumble? – FLBC News (flbcnews.com)
- Summit Health and Humana Inc, reach new network agreement (localdvm.com)
- [$$] Managed Care EPS Quality Improves (finance.yahoo.com)
- Amgen in Collaboration With Humana for Patients’ Benefit (finance.yahoo.com)
- Genuine Parts Co (GPC) and Humana Inc (HUM) Needle Moving on Volume – Evergreen Caller (evergreencaller.com)
Several equities analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $253.00 price objective on the stock in a research report on Thursday, May 18th. BidaskClub lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, June 13th. Citigroup Inc. began coverage on shares of Humana in a research report on Wednesday, June 28th. They set a “buy” rating and a $275.00 price target on the stock. Credit Suisse Group reaffirmed an “outperform” rating and set a $260.00 price target (up from $250.00) on shares of Humana in a research report on Thursday, August 3rd. Finally, Deutsche Bank AG raised their price target on shares of Humana from $234.00 to $243.00 and gave the stock a “hold” rating in a research report on Monday, August 7th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $244.35.
Humana (NYSE HUM) traded down 0.15% on Friday, reaching $247.28. 754,398 shares of the company’s stock traded hands. The firm has a market cap of $35.74 billion, a PE ratio of 20.34 and a beta of 0.91. The firm’s 50-day moving average is $241.05 and its 200 day moving average is $224.57. Humana has a 12 month low of $163.50 and a 12 month high of $255.27.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.08 by $0.41. Humana had a return on equity of 15.85% and a net margin of 3.37%. The company had revenue of $13.53 billion for the quarter, compared to analyst estimates of $13.61 billion. During the same period in the prior year, the company posted $2.30 EPS. Equities analysts predict that Humana will post $11.55 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Tuesday, August 29th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date is Thursday, September 28th. Humana’s dividend payout ratio is presently 13.06%.
In other news, VP M Todoroff Christopher sold 22,935 shares of the stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $252.52, for a total value of $5,791,546.20. Following the transaction, the vice president now directly owns 24,001 shares of the company’s stock, valued at $6,060,732.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce D. Broussard sold 12,000 shares of the stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $251.88, for a total value of $3,022,560.00. Following the completion of the transaction, the chief executive officer now directly owns 80,086 shares in the company, valued at $20,172,061.68. The disclosure for this sale can be found here. Insiders sold 41,406 shares of company stock worth $10,355,086 over the last three months. Corporate insiders own 0.80% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Humana (NYSE:HUM) Earning Somewhat Positive Press Coverage, Analysis Finds” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.com-unik.info/2017/08/19/humana-nysehum-getting-somewhat-favorable-press-coverage-study-shows-updated-updated-updated.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
What are top analysts saying about Humana Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Humana Inc. and related companies.